Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Supportive Care in Cancer
Published in: Supportive Care in Cancer 6/1997

01-11-1997 | ORIGINAL ARTICLE

Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy

Authors: A. J. Sykes, A. E. Kiltie, A. L. Stewart

Published in: Supportive Care in Cancer | Issue 6/1997

Login to get access
Metadata
Title
Ondansetron versus a chlorpromazine and dexamethasone combination for the prevention of nausea and vomiting: a prospective, randomised study to assess efficacy, cost effectiveness and quality of life following single-fraction radiotherapy
Authors
A. J. Sykes
A. E. Kiltie
A. L. Stewart
Publication date
01-11-1997
Publisher
Springer-Verlag
Published in
Supportive Care in Cancer / Issue 6/1997
Print ISSN: 0941-4355
Electronic ISSN: 1433-7339
DOI
https://doi.org/10.1007/s005200050119

Other articles of this Issue 6/1997

Supportive Care in Cancer 6/1997 Go to the issue

ORIGINAL ARTICLE

A pilot study to evaluate the feasibility of using willingness to pay as a measure of value in cancer supportive care: an assessment of amifostine cytoprotection

REVIEW ARTICLE

Problems with opiates in cancer pain: parenteral opioids

REVIEW ARTICLE

Genetic detection: the need for psychosocial support in modern cancer prevention

SHORT COMMUNICATION

Hypersensitivity reactions to parenteral lipid solutions

REVIEW ARTICLE

Organizational barriers in opioid use

ORIGINAL ARTICLE

Peroperative teicoplanin for prevention of gram-positive infections in neutropenic patients with indwelling central venous catheters: a randomized, controlled study
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits